Autek China (300595) Fundamentals 2026 — P/E 21.5x, Revenue Analysis | SniperIQ
Autek China (300595) is a CN-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ¥9.9B, trading at ¥11.03 on the SHZ. This SniperIQ fundamentals page covers Autek China's valuation (P/E 21.5x, P/B 2.0x), profitability (net margin 25.3%), revenue (¥1.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Autek China's market cap?
Autek China (300595) has a market capitalization of approximately ¥9.9B, trading at ¥11.03 on the SHZ. Market cap moves with the live share price.
What is Autek China's P/E ratio?
Autek China's trailing twelve-month P/E ratio is 21.5x, with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Autek China?
Autek China runs a net profit margin of 25.3%, a gross margin of 69.7%, and an operating margin of 30.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Autek China generate?
Autek China reported revenue of ¥1.8B for fiscal year 2025, with net income of ¥480M and earnings per share (EPS) of 0.54. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Autek China pay a dividend?
Autek China offers a trailing dividend yield of about 1.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Autek China financially healthy?
Autek China carries a debt-to-equity ratio of 0.04x and a current ratio of 5.84x, with a market beta of 0.57. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Autek China a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Autek China (300595) the key facts are: market cap ¥9.9B, P/E 21.5x, revenue ¥1.8B, 52-week range 10.19-19.98. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Autek China's full fundamentals live
Get Autek China's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.